ReviewBioMed research international2026
The Oncogenic and Tumor-Suppressive Roles of SNHG18: A Double-Edged Long Noncoding RNA in Cancer.
Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Oncogenic and Tumor-Suppressive Roles of SNHG18: A Double-Edged Long Noncoding RNA in Cancer.BioMed research international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous recent studies have shown that long noncoding RNAs (lncRNAs) play a crucial role in the development of diverse cancers. Small nucleolar RNA host gene 18 (SNHG18) is a cancer-related lncRNA in the SNHG family, whose expression is dysregulated in various tumors and acts as either an oncogenic or tumor-suppressive factor. Several studies have demonstrated that SNHG18 exhibits dual effects in various cancers. The role of this molecule is context-dependent, acting as a tumor suppressor in certain cancers while exhibiting oncogenic properties in others. The expression of SNHG18 is cancer-type specific: it is upregulated in glioma, multiple myeloma, and lung cancer, but downregulated in bladder and hepatocellular cancer. Clinical studies have also found a correlation between SNHG18 expression and prognosis in different cancers. We present an overview of studies on SNHG18, emphasizing its biological functions and its potential as a promising biomarker for the diagnosis and treatment of diverse cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.